Gannex Gets China Nmpa Nod For Phase Ii And Iii Protocols Of Asc42 To Treat Primary Biliary Cholangitis

Gannex Pharma Co., Ltd., A Wholly Owned Company Of Ascletis Pharma Inc. Announces That The Protocols Of Phase Ii And Iii Clinical Trials Of Asc42 To Treat Patients With Primary Biliary Cholangitis (Pbc) Has Been Approved By China National Medical Products Administration (Nmpa).Pbc Is A New Chronic Hepatobiliary Disease Indication Approved For Clinical Trials Of Asc42. The Other Two Chronic Hepatobiliary Disease Indications Approved By China Nmpa And/Or Us Food And Drug Administration (Fda) Are Chronic Hepatitis B (Chb) And Non-Alcoholic Steatohepatitis (Nash).With The Approval Of Asc42 Pbc Phase Ii And Iii Protocols By China Nmpa, Gannex Is Expected To Complete The Phase Ii Trial In 100 Patients Who Have An Inadequate Response To Or Are Unable To Tolerate Ursodeoxycholic Acid (Udca). The Phase Ii Study Consists Of Three Active Treatment Arms And One Placebo Control Arm At The Ratio Of 1:1:1:1 And Is Expected To Complete In The Second Half Of 2022. Gannex Will Initiate The Phase Iii Trial After The Communications With China Nmpa In Terms Of Drug Registration Related Matters Such As Chemistry, Manufacturing And Control (Cmc) And Toxicology Studies.Asc42 Is An In-House Developed, Novel Non-Steroidal, Selective, Potent Farnesoid X Receptor (Fxr) Agonist With Best-In-Class Potential And Global Intellectual Property. The Data From The Us Phase I Trial Of Asc42 Indicated There Was No Pruritus Observed During 14-Day Treatment Of The Once-Daily Human Therapeutic Dose Of 15 Mg And Fxr Target Engagement Biomarker Fgf19 Increased 1,780% On Day 14 Of Treatment With 15 Mg Dose. Furthermore, Mean Ldl-C Values Remained Within The Normal Range During 14-Day, Once Daily Treatment With 15 Mg.Udca Is The Only Drug Which Is Approved In China For Pbc And Approximately 40% Pbc Patients Have An Inadequate Response To Or Are Unable To Tolerate Udca. Obeticholic Acid (Oca), Which Is Not Approved In China, Is The Only Approved Medicine In The Us For Pbc Patients Who Have An Inadequate Response To Or Are Unable To Tolerate Udca. However, There Are Significantly Increased Pruritus Rates And Ldl-C Levels In Patients With Oca Treatment. Lack Of Pruritus And Ldl-C Level Increase At The Therapeutic Dose Makes Asc42 A Potential Best-In-Class Pbc Drug. Gannex Intends To Start A Phase Iii Trial In The Us And European Union After The Completion Of The Phase Ii Study In China.Jidong Jia, Md, Director Of The Liver Disease Center, Beijing Friendship Hospital, Capital Medical University, Deputy Director Of National Clinical Research Center For Digestive Diseases, Stated,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!